Radiopharmaceuticals deploy radiation to damage cancer DNA, but Curie Therapeutics sees these therapies opening the door to a wider range of ways to kill tumors. The startup has raised $75 million in Series A financing to advance its research.
OrbiMed's newest funding is planned to go toward companies focusing on oncology, central nervous system disease and gene editing.
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
International M&A in the life sciences is picking up steam, according to a new Mergermarket report - with new focus on the fields of early stage drug discovery and precision medicine.